Table 2 Demographic and clinical characteristic of patients included in the study of plasmatic levels of In1-ghrelin and ghrelin in control (n = 30) and PCa patients (n = 20)
From: The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness
Parameter | Control (n = 20) | PCa (n = 30) | p value |
|---|---|---|---|
Age, yr., mean (SD) | 63.8 (9.9) | 74.8 (8.1) | < 0,0001 |
Weight, kg, mean (SD) | 82.62 (12.8) | 78.7 (12.3) | 0.29 |
BMI, mean (SD) | 29.8 (4.7) | 28,8 (3.6) | 0.54 |
Total PSA, ng/ml, median (IQR) | 0.85 (0.44–1.1) | 25 (11.1–83.9) | < 0,0001 |
Gleason score, n (%) | |||
 6 |  | 8/30 (26,6%) | - |
 7 |  | 9/30 (30%) | - |
 8 |  | 7/30 (23,3%) | - |
 9 |  | 6/30 (20%) | - |
Acylated In1-ghrelin, pg/mL, median (IQR) | 0 (0–0) | 4.6 (0–18) | 0,03 |